In the phase-2 trials, as many as 60-80% of participants experienced stomach problems, such as nausea, vomiting, diarrhea or constipation, at the higher doses
However, researchers saw that patients were experiencing a reduction in hunger and losing weight, enabling them to be licensed to treat obesity
Gene Set Enrichment Analysis (GSEA) uncovered unique impacts of RETA on key biological processes
The trial participants also showed cardiovascular improvements after taking orforglipron, including lower systolic blood pressure, lower non-HDL cholesterol and lower triglycerides
If you have documented low fasting GLP-1 levels, persistent insulin resistance despite 3-6 months of structured lifestyle change, or genetic predispositions suggesting lower pathway responsiveness, consultation with a healthcare provider about compounded peptide options may be appropriate
This article is for informational purposes only and is not intended as medical advice